Compare Enveric Biosciences Inc (ENVB) vs Hafnia Limited Common Shares (HAFN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hafnia Limited Common Shares — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B). The key difference: Hafnia Limited Common Shares is far larger — about 918.7× Enveric Biosciences Inc's market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Hafnia Limited Common Shares for 0 Days on average.
| ENVB | HAFN | |
|---|---|---|
Market Cap | $6.27M | $5.76B |
Volume | 100,675 | 1,835,725 |
Sector | Health | Industrials |
52-Week High | $10.80 | $10.92 |
52-Week Low | $1.27 | $5.21 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $6.37B |
Dividend Yield | — | 10.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →
